Blood· 2017Q1

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump, Sattva S. Neelapu, Umar Farooq, Éric Van Den Neste et al.

1,700citations
Q1SCImago
2017year

Short summary

In refractory diffuse large B-cell lymphoma (DLBCL), the largest patient-level analysis (n=636) shows a 26% objective response rate and a median overall survival of 6.3 months to subsequent therapy.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Pathology and Forensic Medicine

Pathology and Forensic MedicineMedicine